Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Ramucirumab Shows Promise After Immunotherapy in Advanced Gastroesophageal Cancer
Study suggests ramucirumab may benefit certain patients with advanced gastroesophageal cancer after immunotherapy
Breakthrough Combo Therapy Revolutionizes Advanced Bladder Cancer Treatment
New drug combination shows superior survival benefit for advanced bladder cancer in global trial.
Prostate Cancer Immunotherapy Combo Falls Short in Phase 2 Trial
AZD4635 with durvalumab or oleclumab shows limited efficacy in metastatic castration-resistant prostate cancer
Latest
Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Promising Combo Therapy Shows High Response Rate in High-Risk Melanoma
New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system
Epigenetic-Immunotherapy Combo Shows Promise in Advanced Pancreatic Cancer
Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.
Cannabis Extract Shows Promise in Taming Chemo-Induced Nausea
Oral THC:CBD capsules prove effective against chemotherapy-induced nausea and vomiting in phase II/III trial.
NOBROLA Trial: Olaparib Shows Promise in Rare TNBC Subset Despite Low Enrollment
Phase II trial explores olaparib in TNBC patients with HRD but no BRCA mutations, showing potential benefit.
Unmasking the Risk Factors: New Insights into Immune-Mediated Hepatotoxicity in Cancer Immunotherapy
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
New Hope for Myelofibrosis: Low-Dose Decitabine Shows Promise in Phase 2 Trial
Phase 2 trial reveals potential of low-dose subcutaneous decitabine for treating myelofibrosis cytopenias.
Intensified Chemo Falls Short in Oligometastatic Breast Cancer Study
IACT shows no advantage over CDCT in HRD-positive oligometastatic breast cancer, but long-term survival promising